Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1001 entries
Sorted by: Best Match Show Resources per page
Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.

Seminars in radiation oncology

Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M.
PMID: 10717177
Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185.

Recommendations for the treatment of "poor prognosis" stages I and II Hodgkin's disease (HD) depend on the extent of staging. For centers that favor exploratory laparotomy and splenectomy, the standard treatment after negative surgical staging remains subtotal lymphoid irradiation....

Cite
Cosset JM, Fermé C, Noordijk EM, et al. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996;6(3):185-195doi: 10.1053/SRAO00600185.
Cosset, J. M., Fermé, C., Noordijk, E. M., Dubray, B. M., Thirion, P., & Henry-Amar, M. (1996). Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Seminars in radiation oncology, 6(3), 185-195. https://doi.org/10.1053/SRAO00600185
Cosset, et al. "Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease." Seminars in radiation oncology vol. 6,3 (1996): 185-195. doi: https://doi.org/10.1053/SRAO00600185
Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185. PMID: 10717177.
Copy Download .nbib Format: NLM
Intravenous chemotherapy for ovarian cancer - the state of the art?.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Kaye SB.
PMID: 11240728
Int J Gynecol Cancer. 2000 Jan;10:19-25. doi: 10.1046/j.1525-1438.2000.99506.x.

In 1999, two cytotoxic drug classes have emerged as essential components of intravenous chemotherapy for advanced ovarian cancer: the taxoids and the platinum compounds. Two large-scale randomized trials were required to convince most oncologists (and health care purchasers) that...

Cite
Kaye SB. Intravenous chemotherapy for ovarian cancer - the state of the art?. Int J Gynecol Cancer. 2000;10:19-25doi: 10.1046/j.1525-1438.2000.99506.x.
Kaye, S. B. (2000). Intravenous chemotherapy for ovarian cancer - the state of the art?. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 1019-25. https://doi.org/10.1046/j.1525-1438.2000.99506.x
Kaye, S. B.. "Intravenous chemotherapy for ovarian cancer - the state of the art?." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society vol. 10 (2000): 19-25. doi: https://doi.org/10.1046/j.1525-1438.2000.99506.x
Kaye SB. Intravenous chemotherapy for ovarian cancer - the state of the art?. Int J Gynecol Cancer. 2000 Jan;10:19-25. doi: 10.1046/j.1525-1438.2000.99506.x. PMID: 11240728.
Copy Download .nbib Format: NLM
Role of bevacizumab therapy in the management of glioblastoma.

Cancer management and research

Peak SJ, Levin VA.
PMID: 21188100
Cancer Manag Res. 2010 Apr 22;2:97-104.

Glioblastoma is one of the most common primary brain tumors and one of the most difficult to treat. In population-based studies only 30% of patients will survive 1 year and in the most efficacious surgery, irradiation, and chemotherapy clinical...

Cite
Peak SJ, Levin VA. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res. 2010;2:97-104
Peak, S. J., & Levin, V. A. (2010). Role of bevacizumab therapy in the management of glioblastoma. Cancer management and research, 297-104.
Peak, Scott J, and Levin, Victor A. "Role of bevacizumab therapy in the management of glioblastoma." Cancer management and research vol. 2 (2010): 97-104.
Peak SJ, Levin VA. Role of bevacizumab therapy in the management of glioblastoma. Cancer Manag Res. 2010 Apr 22;2:97-104. PMID: 21188100; PMCID: PMC3004572.
Copy Download .nbib Format: NLM
Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme.

Current oncology (Toronto, Ont.)

Easaw JC, Mason WP, Perry J, Laperrière N, Eisenstat DD, Del Maestro R, Bélanger K, Fulton D, Macdonald D.
PMID: 21655151
Curr Oncol. 2011 Jun;18(3):e126-36. doi: 10.3747/co.v18i3.755.

Recommendation 1: Multidisciplinary ApproachTo optimize treatment outcomes, the management of patients with recurrent glioblastoma should be individualized and should involve a multidisciplinary team approach, including neurosurgery, neuropathology, radiation oncology, neuro-oncology, and allied health professions.Recommendation 2: ImagingThe standard imaging modality...

Cite
Easaw JC, Mason WP, Perry J, et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol. 2011;18(3):e126-36doi: 10.3747/co.v18i3.755.
Easaw, J. C., Mason, W. P., Perry, J., Laperrière, N., Eisenstat, D. D., Del Maestro, R., Bélanger, K., Fulton, D., Macdonald, D. (2011). Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Current oncology (Toronto, Ont.), 18(3), e126-36. https://doi.org/10.3747/co.v18i3.755
Easaw, J C, et al. "Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme." Current oncology (Toronto, Ont.) vol. 18,3 (2011): e126-36. doi: https://doi.org/10.3747/co.v18i3.755
Easaw JC, Mason WP, Perry J, Laperrière N, Eisenstat DD, Del Maestro R, Bélanger K, Fulton D, Macdonald D. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol. 2011 Jun;18(3):e126-36. doi: 10.3747/co.v18i3.755. PMID: 21655151; PMCID: PMC3108873.
Copy Download .nbib Format: NLM
Antimicrobial therapy of peptic ulcers.

International journal of antimicrobial agents

Miehlke S, Graham DY.
PMID: 18611798
Int J Antimicrob Agents. 1997;8(3):171-8. doi: 10.1016/s0924-8579(97)00368-3.

It is now accepted that peptic ulcer disease, whether duodenal or gastric, is one manifestation of infection with the bacterium Helicobacter pylori. This realization has revolutionized the management of peptic ulcer disease and changed the dictum from no acid...

Cite
Miehlke S, Graham DY. Antimicrobial therapy of peptic ulcers. Int J Antimicrob Agents. 1997;8(3):171-8doi: 10.1016/s0924-8579(97)00368-3.
Miehlke, S., & Graham, D. Y. (1997). Antimicrobial therapy of peptic ulcers. International journal of antimicrobial agents, 8(3), 171-8. https://doi.org/10.1016/s0924-8579(97)00368-3
Miehlke, S, and Graham, D Y. "Antimicrobial therapy of peptic ulcers." International journal of antimicrobial agents vol. 8,3 (1997): 171-8. doi: https://doi.org/10.1016/s0924-8579(97)00368-3
Miehlke S, Graham DY. Antimicrobial therapy of peptic ulcers. Int J Antimicrob Agents. 1997;8(3):171-8. doi: 10.1016/s0924-8579(97)00368-3. PMID: 18611798.
Copy Download .nbib Format: NLM
In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis.

International journal of antimicrobial agents

Kerr JR.
PMID: 18611561
Int J Antimicrob Agents. 1993;3(3):205-9. doi: 10.1016/0924-8579(93)90013-u.

This study utilised the killing curve method to determine the in vitro effects of all possible two drug combinations of ceftazidine, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against 10 strains of Pseudomonas cepacia isolated from the sputa of...

Cite
Kerr JR. In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. Int J Antimicrob Agents. 1993;3(3):205-9doi: 10.1016/0924-8579(93)90013-u.
Kerr, J. R. (1993). In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. International journal of antimicrobial agents, 3(3), 205-9. https://doi.org/10.1016/0924-8579(93)90013-u
Kerr, J R. "In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis." International journal of antimicrobial agents vol. 3,3 (1993): 205-9. doi: https://doi.org/10.1016/0924-8579(93)90013-u
Kerr JR. In vitro activities of two drug combinations of ceftazidime, cefotaxime, cefuroxime, ciprofloxacin, chloramphenicol, imipenem and temocillin against clinical isolates of Pseudomonas cepacia from patients with cystic fibrosis. Int J Antimicrob Agents. 1993;3(3):205-9. doi: 10.1016/0924-8579(93)90013-u. PMID: 18611561.
Copy Download .nbib Format: NLM
Drug discovery: engineering drug combinations.

Nature chemical biology

Dixon SJ, Stockwell BR.
PMID: 20404820
Nat Chem Biol. 2010 May;6(5):318-9. doi: 10.1038/nchembio.353.

No abstract available.

Cite
Dixon SJ, Stockwell BR. Drug discovery: engineering drug combinations. Nat Chem Biol. 2010;6(5):318-9doi: 10.1038/nchembio.353.
Dixon, S. J., & Stockwell, B. R. (2010). Drug discovery: engineering drug combinations. Nature chemical biology, 6(5), 318-9. https://doi.org/10.1038/nchembio.353
Dixon, Scott J, and Stockwell, Brent R. "Drug discovery: engineering drug combinations." Nature chemical biology vol. 6,5 (2010): 318-9. doi: https://doi.org/10.1038/nchembio.353
Dixon SJ, Stockwell BR. Drug discovery: engineering drug combinations. Nat Chem Biol. 2010 May;6(5):318-9. doi: 10.1038/nchembio.353. PMID: 20404820; PMCID: PMC3048766.
Copy Download .nbib Format: NLM
The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.

American journal of cancer research

Chou TC.
PMID: 22016837
Am J Cancer Res. 2011;1(7):925-54. Epub 2011 Aug 05.

The mass-action law based system analysis via mathematical induction and deduction lead to the generalized theory and algorithm that allows computerized simulation of dose-effect dynamics with small size experiments using a small number of data points in vitro, in...

Cite
Chou TC. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res. 2011;1(7):925-54
Chou, T. C. (2011). The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. American journal of cancer research, 1(7), 925-54.
Chou, Ting-Chao. "The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development." American journal of cancer research vol. 1,7 (2011): 925-54.
Chou TC. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res. 2011;1(7):925-54. Epub 2011 Aug 05. PMID: 22016837; PMCID: PMC3196289.
Copy Download .nbib Format: NLM
Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

Viruses

Wainberg MA, Brenner BG.
PMID: 21994627
Viruses. 2010 Nov;2(11):2493-508. doi: 10.3390/v2112493. Epub 2010 Nov 11.

Despite the fact that over 90% of HIV-1 infected people worldwide harbor non-subtype B variants of HIV-1, knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited. Due to historical delays in access to antiretroviral therapy...

Cite
Wainberg MA, Brenner BG. Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses. 2010;2(11):2493-508doi: 10.3390/v2112493.
Wainberg, M. A., & Brenner, B. G. (2010). Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses, 2(11), 2493-508. https://doi.org/10.3390/v2112493
Wainberg, Mark A, and Brenner, Bluma G. "Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs." Viruses vol. 2,11 (2010): 2493-508. doi: https://doi.org/10.3390/v2112493
Wainberg MA, Brenner BG. Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. Viruses. 2010 Nov;2(11):2493-508. doi: 10.3390/v2112493. Epub 2010 Nov 11. PMID: 21994627; PMCID: PMC3185584.
Copy Download .nbib Format: NLM
Efficacy and tolerability of multidrug therapy for hypertriglyceridemia.

Journal of clinical lipidology

Polsani VR, Nambi V, Virani SS, Zoch D, Yang EY, Jones PH, Ballantyne CM.
PMID: 21291832
J Clin Lipidol. 2009 Oct;3(5):341-4. doi: 10.1016/j.jacl.2009.09.003. Epub 2009 Sep 15.

BACKGROUND: Although there is clinical evidence for the safety and efficacy of single-drug therapy and some two-drug combinations for the treatment of hypertriglyceridemia, information is limited on the use of more than 2 drugs.OBJECTIVE: We evaluated the efficacy and...

Cite
Polsani VR, Nambi V, Virani SS, et al. Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. J Clin Lipidol. 2009;3(5):341-4doi: 10.1016/j.jacl.2009.09.003.
Polsani, V. R., Nambi, V., Virani, S. S., Zoch, D., Yang, E. Y., Jones, P. H., & Ballantyne, C. M. (2009). Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. Journal of clinical lipidology, 3(5), 341-4. https://doi.org/10.1016/j.jacl.2009.09.003
Polsani, Venkateshwar R, et al. "Efficacy and tolerability of multidrug therapy for hypertriglyceridemia." Journal of clinical lipidology vol. 3,5 (2009): 341-4. doi: https://doi.org/10.1016/j.jacl.2009.09.003
Polsani VR, Nambi V, Virani SS, Zoch D, Yang EY, Jones PH, Ballantyne CM. Efficacy and tolerability of multidrug therapy for hypertriglyceridemia. J Clin Lipidol. 2009 Oct;3(5):341-4. doi: 10.1016/j.jacl.2009.09.003. Epub 2009 Sep 15. PMID: 21291832.
Copy Download .nbib Format: NLM
Drug targets and predictive biomarkers in the management of metastatic melanoma.

Pharmacogenomics and personalized medicine

Thumar J, Giesen E, Kluger HM.
PMID: 23226069
Pharmgenomics Pers Med. 2012;5:139-48. doi: 10.2147/PGPM.S25100. Epub 2012 Sep 28.

Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma...

Cite
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med. 2012;5:139-48doi: 10.2147/PGPM.S25100.
Thumar, J., Giesen, E., & Kluger, H. M. (2012). Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmacogenomics and personalized medicine, 5139-48. https://doi.org/10.2147/PGPM.S25100
Thumar, Jaykumar, et al. "Drug targets and predictive biomarkers in the management of metastatic melanoma." Pharmacogenomics and personalized medicine vol. 5 (2012): 139-48. doi: https://doi.org/10.2147/PGPM.S25100
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med. 2012;5:139-48. doi: 10.2147/PGPM.S25100. Epub 2012 Sep 28. PMID: 23226069; PMCID: PMC3513235.
Copy Download .nbib Format: NLM
Comparison of two drug combinations in total intravenous anesthesia: Propofol-ketamine and propofol-fentanyl.

Saudi journal of anaesthesia

Singh Bajwa SJ, Bajwa SK, Kaur J.
PMID: 20927266
Saudi J Anaesth. 2010 May;4(2):72-9. doi: 10.4103/1658-354X.65132.

BACKGROUND AND AIMS: Keeping in consideration the merits of total intravenous anesthesia (TIVA), a genuine attempt was made to find the ideal drug combinations which can be used in general anesthesia. This study was conducted to evaluate and compare...

Cite
Singh Bajwa SJ, Bajwa SK, Kaur J. Comparison of two drug combinations in total intravenous anesthesia: Propofol-ketamine and propofol-fentanyl. Saudi J Anaesth. 2010;4(2):72-9doi: 10.4103/1658-354X.65132.
Singh Bajwa, S. J., Bajwa, S. K., & Kaur, J. (2010). Comparison of two drug combinations in total intravenous anesthesia: Propofol-ketamine and propofol-fentanyl. Saudi journal of anaesthesia, 4(2), 72-9. https://doi.org/10.4103/1658-354X.65132
Singh Bajwa, Sukhminder Jit, et al. "Comparison of two drug combinations in total intravenous anesthesia: Propofol-ketamine and propofol-fentanyl." Saudi journal of anaesthesia vol. 4,2 (2010): 72-9. doi: https://doi.org/10.4103/1658-354X.65132
Singh Bajwa SJ, Bajwa SK, Kaur J. Comparison of two drug combinations in total intravenous anesthesia: Propofol-ketamine and propofol-fentanyl. Saudi J Anaesth. 2010 May;4(2):72-9. doi: 10.4103/1658-354X.65132. PMID: 20927266; PMCID: PMC2945518.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1001 entries